Oncotarget

Meta-Analysis:

Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis

Xianyun Zhang, Chuntao Fang, Guangbo Zhang, Fujin Jiang, Lei Wang and Jianquan Hou _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:93156-93167. https://doi.org/10.18632/oncotarget.21114

Metrics: PDF 1700 views  |   HTML 2659 views  |   ?  


Abstract

Xianyun Zhang1,2,*, Chuntao Fang3,*, Guangbo Zhang4, Fujin Jiang2, Lei Wang2 and Jianquan Hou1

1Department of Urology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

2Department of Urology, The Affiliated Huai'an Hospital of Xuzhou Medical University, The Second People's Hospital of Huai'an, Huai’an, Jiangsu, China

3Department of Gynaecology, The Affiliated Huai'an Hospital of Xuzhou Medical University, The Second People's Hospital of Huai'an, Huai’an, Jiangsu, China

4Clinical Immunology Laboratory, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

*These authors contributed equally to this work

Correspondence to:

Jianquan Hou, email: [email protected]

Keywords: B7-H3, solid tumor, survival, prognostic biomarker, meta-analysis

Received: December 20, 2016     Accepted: September 03, 2017     Published: September 21, 2017

ABSTRACT

Increasing evidence suggests B7-H3 is aberrantly expressed in various cancers, though its prognostic significance in solid tumors remains controversial. We therefore performed a meta-analysis to clarify the prognostic value of B7-H3 expression in human solid tumors. The PubMed and Embase databases were searched, and 28 studies involving 4623 patients were ultimately included in the analysis. Hazard ratios (HRs) with 95% confidence intervals (CIs) were utilized as effect estimates to evaluate the association between B7-H3 expression and overall survival (OS), progression-free survival (PFS) and recurrence-free survival (RFS). The pooled results showed B7-H3 was associated with poor OS (HR = 1.58; 95% CI: 1.32–1.90; P < 0.00001) and PFS (HR = 1.67; 95% CI: 1.05–2.65; P = 0.031), but not RFS (HR = 1.17; 95% CI: 0.89–1.53; P = 0.267). These results suggest B7-H3 is a negative predictor of OS and PFS in patients with solid tumors. B7-H3 may thus be a useful prognostic biomarker and therapeutic target for human solid tumors. However, further studies will be needed to more precisely determine the prognostic value of B7 H3 expression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21114